A Breath of Fresh Air
for Paroxysmal Atrial
Fibrillation (PAF) patients.

More than 12 million patients suffer from PAF worldwide. InCarda is developing an inhaled anti-arrhythmic drug that could be patient-administered and more quickly and safely convert patients back to normal sinus rhythm.

Meeting an Unmet Need:
The Global Prevalence of Atrial Fibrillation (AF),
Over 34 Million & Growing

Prevalence of Atrial Fibrillation and Flutter (per 100,000) by Region, 2010

Atrial fibrillation remains a significant unmet medical need. Current therapeutic and interventional options are inadequate and the incidence of AF is projected to grow significantly over the coming years. It is currently treated either through pharmacological intervention with a combination of rhythm control, rate control and anticoagulation therapies; electrical cardioversion; and/or catheter ablation. PAF results in high direct and indirect costs including physician visits, ER visits and extended hospital stays, in addition to costs related to complications as a result of invasive procedures.

InCarda Therapeutics Recruiting for Phase 2 Clinical Trial in PAF